Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 13 04:00PM ET
11.77
Dollar change
-0.58
Percentage change
-4.70
%
Index- P/E- EPS (ttm)-5.28 Insider Own10.76% Shs Outstand23.22M Perf Week4.81%
Market Cap273.30M Forward P/E- EPS next Y-4.15 Insider Trans3.45% Shs Float20.72M Perf Month12.74%
Income-21.48M PEG- EPS next Q-0.86 Inst Own67.39% Short Float0.17% Perf Quarter39.79%
Sales0.00M P/S- EPS this Y48.42% Inst Trans27.20% Short Ratio0.87 Perf Half Y61.01%
Book/sh3.59 P/B3.28 EPS next Y-34.15% ROA-43.53% Short Interest0.04M Perf Year267.81%
Cash/sh2.92 P/C4.02 EPS next 5Y- ROE-48.23% 52W Range2.69 - 13.22 Perf YTD264.40%
Dividend Est.- P/FCF- EPS past 5Y- ROI-33.46% 52W High-10.97% Beta0.88
Dividend TTM- Quick Ratio15.01 Sales past 5Y-42.37% Gross Margin- 52W Low337.55% ATR (14)0.90
Dividend Ex-Date- Current Ratio15.01 EPS Y/Y TTM54.50% Oper. Margin- RSI (14)56.91 Volatility12.50% 8.26%
Employees16 Debt/Eq0.00 Sales Y/Y TTM-100.00% Profit Margin- Recom1.17 Target Price25.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q82.78% Payout- Rel Volume1.28 Prev Close12.35
Sales Surprise- EPS Surprise12.73% Sales Q/Q- EarningsNov 14 AMC Avg Volume40.76K Price11.77
SMA2010.49% SMA5011.59% SMA20038.66% Trades Volume52,248 Change-4.70%
Date Action Analyst Rating Change Price Target Change
TodayInitiated Robert W. Baird Outperform $30
Oct-16-24Initiated Oppenheimer Outperform $35
Sep-12-24Initiated Guggenheim Buy $17
Jul-22-24Initiated Leerink Partners Outperform $13
Jun-13-24Initiated Piper Sandler Overweight $30
Oct-05-20Downgrade Ladenburg Thalmann Buy → Neutral
Apr-20-20Initiated Ladenburg Thalmann Buy $14
Feb-26-16Downgrade Maxim Group Buy → Hold
Dec-31-15Reiterated Maxim Group Buy $23 → $14
Sep-16-15Reiterated Maxim Group Buy $4 → $23
Dec-09-24 09:55AM
08:50AM
Nov-26-24 07:00AM
Nov-14-24 04:30PM
Nov-04-24 08:00AM
05:01PM Loading…
Oct-25-24 05:01PM
Oct-14-24 06:00AM
Oct-12-24 06:30AM
Sep-30-24 09:03PM
Sep-26-24 04:30PM
Sep-18-24 08:00AM
Sep-17-24 08:00AM
Jul-15-24 06:00AM
Jul-01-24 07:00AM
May-13-24 02:53PM
08:15AM Loading…
08:15AM
May-01-24 08:00AM
Apr-18-24 07:30AM
07:00AM
Apr-09-24 08:00AM
Mar-24-24 07:55AM
Feb-13-24 08:00AM
Nov-30-23 07:00AM
Nov-17-23 08:00AM
Nov-13-23 08:00AM
Sep-21-23 08:00AM
Aug-21-23 09:02PM
Aug-18-23 09:02PM
Aug-11-23 01:00PM
Aug-08-23 10:30PM
01:00PM Loading…
Jul-25-23 01:00PM
Jun-26-23 08:00AM
May-15-23 08:00AM
May-08-23 08:05AM
08:00AM
Feb-13-23 08:00AM
Jan-23-23 09:48AM
Nov-10-22 08:00AM
Sep-16-22 08:42AM
Sep-12-22 10:06PM
Sep-02-22 08:00AM
Jul-15-22 06:52AM
May-16-22 08:15AM
Feb-14-22 08:00AM
Jan-18-22 12:53PM
Jan-17-22 09:30AM
Nov-27-21 06:54AM
Nov-15-21 08:00AM
Sep-20-21 08:00AM
Sep-13-21 03:58PM
Sep-08-21 08:10AM
08:05AM
08:00AM
May-31-21 01:54AM
Apr-27-21 09:55PM
04:44PM
Mar-23-21 12:18PM
07:24AM
07:09AM
Feb-24-21 09:26AM
08:29AM
Dec-07-20 02:33PM
Dec-02-20 12:06AM
Oct-06-20 04:05PM
Oct-02-20 09:05AM
Sep-23-20 04:54PM
Sep-01-20 08:15AM
Jul-08-20 08:00AM
Apr-20-20 06:49AM
Apr-15-20 08:52AM
Apr-14-20 09:28PM
Mar-30-20 10:09AM
Mar-26-20 09:44AM
Feb-27-20 06:18PM
Jan-31-20 08:08AM
Nov-27-19 08:00AM
Nov-17-19 07:02PM
Nov-15-19 07:00AM
Oct-31-19 08:30AM
Sep-30-19 09:24AM
Sep-19-19 09:15AM
Sep-16-19 08:00AM
Sep-15-19 09:49PM
Jul-31-19 08:30AM
Jul-11-19 11:34PM
Jun-06-19 08:09AM
May-08-19 08:01PM
Mar-06-19 09:52PM
Jan-29-19 09:46PM
Dec-21-18 10:10AM
Nov-23-18 12:01AM
Nov-15-18 07:35AM
Sep-19-18 08:00AM
Jul-14-18 02:02PM
Jul-10-18 05:15PM
08:10AM
07:30AM
Jul-09-18 11:04AM
Jul-08-18 08:59PM
May-31-18 08:00AM
Benitec Biopharma, Inc. is a development-stage biotechnology company, which engages in the advancement of novel genetic medicines. The firm's proprietary platforms include DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitates sustained silencing of disease-causing genes following a single administration. It is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy and Chronic Hepatitis B. The company was founded in 1995 and is headquartered in Hayward, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SUVRETTA CAPITAL MANAGEMENT, LDirectorDec 03 '24Buy9.6042,000403,2007,957,365Dec 05 04:36 PM
SUVRETTA CAPITAL MANAGEMENT, LDirectorNov 20 '24Buy10.2227,436280,3967,920,175Nov 21 04:24 PM
SUVRETTA CAPITAL MANAGEMENT, LDirectorNov 19 '24Buy9.7314,000136,2207,895,815Nov 21 04:24 PM